The small-molecule inhibitors of p53-murine double minute 2 interaction, such as
Nutlin-3, are effective against
cancers bearing wild-type p53. However, murine double minute 2 inhibitors often are unable to completely eliminate solid
tumor cells. To address this issue, we investigated the anticancer effects of
Nutlin-3 in combination with
Oridonin in
osteosarcoma cells. We found that
Oridonin at sub-toxic concentrations synergistically enhanced Nutlin-3-mediated cell viability inhibition in wild-type p53 U2OS and SJSA-1, but not in p53-mutant
MNNG/HOS and in null-p53 Saos-2
osteosarcoma cell lines. Importantly, in the presence of
Oridonin,
Nutlin-3 could completely abolish cell viability in the wild-type p53
osteosarcoma cell lines. Western blotting analysis showed that
Oridonin treatment rapidly and distinctly increased the levels of all three forms of Bim and also markedly reduced the levels of Bcl-2 and Bcl-xl in
osteosarcoma cells. Western blotting analysis further showed that
Oridonin considerably enhanced Nutlin-3-triggered activation of caspases-9 and -3 and
poly(ADP-ribose) polymerase cleavage. Flow cytometry assay showed that
Oridonin significantly enhanced Nutlin-3-mediated apoptosis in wild-type p53
osteosarcoma cells. Overall, our results suggest that the combined treatment of
Nutlin-3 plus
Oridonin may offer a novel therapeutic strategy for
osteosarcoma.